Transcatheter Closure of Atrial Septal Defects using the GORE® Septal Occluder in Children Less Than 10 kg of Body Weight

详细信息    查看全文

• 作者：Tariq Abu-Tair ; Christiane M. Wiethoff ; Jascha Kehr…
• 关键词：Congenital heart disease ; Device closure ; Occluder ; Paediatric ; Atrial septal defect
• 刊名：Pediatric Cardiology
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：37
• 期：4
• 页码：778-783
• 全文大小：554 KB
• 参考文献：1.Agnoletti G et al (2005) Complications of paediatric interventional catheterisation: an analysis of risk factors. Cardiol Young 15(4):402–408CrossRef PubMed
  2.Amin Z (2014) Echocardiographic predictors of cardiac erosion after Amplatzer septal occluder placement. Catheter Cardiovasc Interv 83(1):84–92CrossRef PubMed
  3.Amin Z et al (2004) Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: review of registry of complications and recommendations to minimize future risk. Catheter Cardiovasc Interv 63(4):496–502CrossRef PubMed
  4.Amplatzer Medical Corporation, Septal Occluder and delivery system. 2007. http://​manuals.​sjm.​com/​Search-Form?​re=​North-America&​cc=​US&​ln=​all&​fam=​db52be0a-e057-428d-9897-67e1e67f542e&​cat=​71260c89-7cb8-475d-950b-0262191e7526&​seg=​dd28d64f-7d0b-4660-aa2c-da987bb7894c&​ipp=​10
  5.Andrews R et al (2002) Atrial septal defect with failure to thrive in infancy: hidden pulmonary vascular disease? Pediatr Cardiol 23(5):528–530CrossRef PubMed
  6.Bartakian S et al (2013) Prospective randomized trial of transthoracic echocardiography versus transesophageal echocardiography for assessment and guidance of transcatheter closure of atrial septal defects in children using the Amplatzer septal occluder. JACC Cardiovasc Interv 6(9):974–980CrossRef PubMed
  7.Behjati-Ardakani M, Sadr-Bafghi SM, Andishmand A (2012) Combined transcatheter closure of atrial septal defect and pulmonary valve balloon dilation. Acta Med Iran 50(10):710–712PubMed
  8.Bishnoi RN et al (2014) Device closure of secundum atrial septal defects in infants weighing less than 8 kg. Pediatr Cardiol 35(7):1124–1131CrossRef PubMed
  9.Crawford GB et al (2012) Percutaneous atrial septal occluder devices and cardiac erosion: a review of the literature. Catheter Cardiovasc Interv 80(2):157–167CrossRef PubMed
  10.El-Said H et al (2015) Device therapy for atrial septal defects in a multicenter cohort: acute outcomes and adverse events. Catheter Cardiovasc Interv 85(2):227–233CrossRef PubMed
  11.Erdem A et al (2013) Transthoracic echocardiographic guidance during transcatheter closure of atrial septal defects in children and adults. Int J Cardiovasc Imaging 29(1):53–61CrossRef PubMed
  12.Grohmann J et al (2014) Transcatheter closure of atrial septal defects in children and adolescents: single-center experience with the GORE(R) septal occluder. Catheter Cardiovasc Interv 84(6):E51–E57CrossRef PubMed
  13.Javois AJ et al (2014) Results of the U.S. Food and Drug Administration continued access clinical trial of the GORE HELEX septal occluder for secundum atrial septal defect. JACC Cardiovasc Interv 7(8):905–912CrossRef PubMed
  14.Kazmouz S et al (2013) Transcatheter closure of secundum atrial septal defects. J Invasive Cardiol 25(5):257–264PubMed
  15.Kin H et al (1997) Effects of balloon pulmonary valvuloplasty on atrial shunting–a patient with pulmonary valve stenosis and a large secundum atrial septal defect. Jpn Circ J 61(2):192–196CrossRef PubMed
  16.Knop M et al (2014) Transcatheter closure of atrial septal defect in children up to 10 kg of body weight with Amplatzer device. Cardiol J 21(3):279–283CrossRef PubMed
  17.Kutty S et al (2012) Long-term (5- to 20-year) outcomes after transcatheter or surgical treatment of hemodynamically significant isolated secundum atrial septal defect. Am J Cardiol 109(9):1348–1352CrossRef PubMed
  18.Lammers A et al (2005) Need for closure of secundum atrial septal defect in infancy. J Thorac Cardiovasc Surg 129(6):1353–1357CrossRef PubMed
  19.Lo MH et al (2011) Impact of transcatheter closure of atrial septal defects in pediatric patients on body weight. J Formos Med Assoc 110(7):467–472CrossRef PubMed
  20.Miga DE et al (1997) Incidence of femoral vein occlusion after catheter ablation in children: evaluation with magnetic resonance angiography. Pediatr Cardiol 18(3):204–207CrossRef PubMed
  21.Monfredi O et al (2013) Percutaneous device closure of atrial septal defect results in very early and sustained changes of right and left heart function. Int J Cardiol 167(4):1578–1584CrossRef PubMed
  22.Nakasato M et al (1997) Balloon pulmonary valvuloplasty for pulmonary valve stenosis with atrial septal defect. Am J Cardiol 79(6):838–839CrossRef PubMed
  23.Nyboe C, Hjortdal VE, Nielsen-Kudsk JE (2013) First experiences with the GORE((R)) septal occluder in children and adults with atrial septal defects. Catheter Cardiovasc Interv 82(6):929–934CrossRef PubMed
  24.Pawelec-Wojtalik M et al (2006) Comparison of cardiac function in children after surgical and Amplatzer occluder closure of secundum atrial septal defects. Eur J Cardiothorac Surg 29(1):89–92CrossRef PubMed
  25.Rhodes JF Jr, Goble J (2014) Combined prospective United States clinical study data for the GORE((R)) HELEX((R)) septal occluder device. Catheter Cardiovasc Interv 83(6):944–952CrossRef PubMed
  26.Smith B et al (2014) UK multicenter experience using the gore septal occluder (GSO(TM)) for atrial septal defect closure in children and adults. Catheter Cardiovasc Interv 83(4):581–586CrossRef PubMed
  27.Thomas VC et al (2012) Transcatheter closure of secundum atrial septal defect in infants less than 12 months of age improves symptoms of chronic lung disease. Congenit Heart Dis 7(3):204–211CrossRef PubMed
  28.U.S. Food and Drug Administration, Rare Serious Erosion Events Associated with St. Jude Amplatzer Atrial Septal Occluder (ASO): FDA Safety Communication. 2013 10.10.2015. http://​www.​fda.​gov/​medicaldevices/​safety/​Alertsandnotices​/​ucm371145.​htm
  29.Vitiello R et al (1998) Complications associated with pediatric cardiac catheterization. J Am Coll Cardiol 32(5):1433–1440CrossRef PubMed
  30.Wood AM et al (2011) Transcatheter elimination of left-to-right shunts in infants with bronchopulmonary dysplasia is feasible and safe. Congenit Heart Dis 6(4):330–337CrossRef PubMed
  31.Zanjani KS et al (2011) Transcatheter atrial septal defect closure under transthorasic echocardiography in children. Iran J Pediatr 21(4):473–478PubMed PubMedCentral
  
• 作者单位：Tariq Abu-Tair (1)
  Christiane M. Wiethoff (1)
  Jascha Kehr (1)
  Wlodzimierz Kuroczynski (1)
  Christoph Kampmann (1)
  
  1. Department of Pediatric Cardiology and Congenital Heart Disease, University Children’s Hospital, University Medicine Mainz, Langenbeckstr. 1, 55131, Mainz, Germany
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Cardiology
  Cardiac Surgery
  Vascular Surgery
  
• 出版者：Springer New York
• ISSN：1432-1971

文摘

The GORE® Septal Occluder (GSO) is a well-evaluated device for interventional ASD closure with closure rates comparable to the Amplatzer® Septal Occluder (ASO), but there are no published reports of its use in small children weighing less than 10 kg. This may be due to the necessity of a large-sized introducing sheath of at least 10 Fr and therefore the assumed risk of complications in vascular access. The GSO is an alternative option for interventional ASD closure in children weighing less than 10 kg. Fourteen infants and children with a median body weight 8900 g (range 6350–9650 g) underwent successful ASD closure using the GSO. The closure was performed under fluoroscopic and transthoracic echocardiographic guidance. Postprocedure, the vessels passed by the occluder and delivery catheter were examined by duplex sonography. The median ASD diameter was 11 mm (5–17 mm), and the median GSO size was 22.5 mm (15–30 mm), whereas the median ASO left disc size that would have been recommended was 25 mm (17–31 mm). All ASDs were successfully closed. During a median follow-up of 1.57 years (range 0.5–4.2), no complications like erosion, embolization, arrhythmias, or vascular injuries occurred. Although using a 10-Fr introducer sheath, no vascular complications were detected. Our data suggest that the small usable size as well as the soft and flexible design of the device allows successful use of the GSO in young children.